These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22293236)

  • 21. Quality by design approach for formulation development: a case study of dispersible tablets.
    Charoo NA; Shamsher AA; Zidan AS; Rahman Z
    Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of quality-by-design analytical methods.
    Vogt FG; Kord AS
    J Pharm Sci; 2011 Mar; 100(3):797-812. PubMed ID: 21280050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review.
    Tomba E; Facco P; Bezzo F; Barolo M
    Int J Pharm; 2013 Nov; 457(1):283-97. PubMed ID: 24016743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of quality by design to the development of analytical separation methods.
    Orlandini S; Pinzauti S; Furlanetto S
    Anal Bioanal Chem; 2013 Jan; 405(2-3):443-50. PubMed ID: 22941176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of QbD for the development of a vaccine candidate.
    Haas J; Franklin A; Houser M; Maraldo D; Mikola M; Ortiz R; Sullivan E; Otero JM
    Vaccine; 2014 May; 32(24):2927-30. PubMed ID: 24598725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QbD implementation and Post Approval Lifecycle Management (PALM).
    Ohage E; Iverson R; Krummen L; Taticek R; Vega M
    Biologicals; 2016 Sep; 44(5):332-40. PubMed ID: 27449920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Process Analytical Technology for Crystallization of Active Pharmaceutical Ingredients.
    Malwade CR; Qu H
    Curr Pharm Des; 2018; 24(21):2456-2472. PubMed ID: 29956616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach.
    Simões A; Veiga F; Vitorino C; Figueiras A
    J Pharm Sci; 2018 Oct; 107(10):2653-2662. PubMed ID: 29935297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of a stability-indicating method by Quality-by-Design versus Quality-by-Testing: a case of a learning process.
    Hubert C; Lebrun P; Houari S; Ziemons E; Rozet E; Hubert P
    J Pharm Biomed Anal; 2014 Jan; 88():401-9. PubMed ID: 24176744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality by Design for enabling RNA platform production processes.
    Daniel S; Kis Z; Kontoravdi C; Shah N
    Trends Biotechnol; 2022 Oct; 40(10):1213-1228. PubMed ID: 35491266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality-by-design: are we there yet?
    Cook J; Cruañes MT; Gupta M; Riley S; Crison J
    AAPS PharmSciTech; 2014 Feb; 15(1):140-8. PubMed ID: 24218058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quality by design study applied to an industrial pharmaceutical fluid bed granulation.
    Lourenço V; Lochmann D; Reich G; Menezes JC; Herdling T; Schewitz J
    Eur J Pharm Biopharm; 2012 Jun; 81(2):438-47. PubMed ID: 22446063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems.
    Mehrotra S; Salwa A; Kumar L
    Crit Rev Ther Drug Carrier Syst; 2023; 40(3):1-46. PubMed ID: 36749082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.
    Pallagi E; Ambrus R; Szabó-Révész P; Csóka I
    Int J Pharm; 2015 Aug; 491(1-2):384-92. PubMed ID: 26134895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Quality by design approaches for pharmaceutical development and manufacturing of Chinese medicine].
    Xu B; Shi XY; Wu ZS; Zhang YL; Wang Y; Qiao YJ
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1015-1024. PubMed ID: 29027410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current challenges and recent advances on the path towards continuous biomanufacturing.
    Drobnjakovic M; Hart R; Kulvatunyou BS; Ivezic N; Srinivasan V
    Biotechnol Prog; 2023; 39(6):e3378. PubMed ID: 37493037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploiting mAb structure characteristics for a directed QbD implementation in early process development.
    Karlberg M; von Stosch M; Glassey J
    Crit Rev Biotechnol; 2018 Sep; 38(6):957-970. PubMed ID: 29514519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of quality by design in the current drug development.
    Zhang L; Mao S
    Asian J Pharm Sci; 2017 Jan; 12(1):1-8. PubMed ID: 32104308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.